Innovative Industrial Properties, Inc. Q2 FY2025 earnings call

• Announced first expansion outside cannabis industry with investment in IQHQ, a leading private life science REIT. IQHQ has over 5 million sq ft of portfolio and pipeline in top life science markets.
• Updates on cannabis portfolio: 4Front Ventures in bankruptcy, Gold Flora in receivership, PharmaCann legal proceedings to regain properties, TILT Holdings making partial rent payments. Also, re-leasing activity in Michigan and Pennsylvania.
• Ben Regin mentioned robust pipeline including cannabis investments and life science opportunities, with IQHQ providing right of first offer for future asset sales.

For the second quarter, total revenues were $62.9 million, a 12% decrease from the first quarter due to tenant defaults. Adjusted funds from operations (AFFO) was $48.4 million or $1.71 per share, a 12% decrease from the first quarter. The company also announced a strategic investment in IQHQ, a leading private life science REIT, with a total commitment of $270 million expected to be accretive to AFFO and carrying a blended yield exceeding 14%.

• IQHQ investment is expected to be highly accretive to AFFO with a blended yield exceeding 14%.
• Overall pipeline remains robust including both cannabis investments and life science opportunities, focusing on highest quality investments with attractive risk-adjusted returns.

• Macroeconomic uncertainty and unpredictable regulatory backdrop in cannabis industry.
• Illicit market competition affecting regulated cannabis markets.
• Challenges in the life science sector with past difficulties for existing owners and uncertain recovery timelines.

Q: Walk us through the real estate investment case for IQHQ, business plan, how company is overcoming challenges, and why now is right time to invest?

A: Alan D. Gold and Ben Regin discussed IQHQ's position in the capital stack, accretive nature, and recovery potential in life science industry with attractive risk-adjusted returns.

Q: Opportunity cost of capital for IQHQ vs buying back shares?

A: Alan D. Gold said market volatility not way to run business, overall cost of capital considered makes IQHQ investment accretive.

Q: Decision to diversify from cannabis related to dividend and defaults?

A: Alan D. Gold said strategic evaluation of opportunities outside cannabis, IQHQ provided current income and yield meeting high cost of capital.

Q: Why structure of revolver and preferred plus warrant more attractive than direct investment in life sciences?

A: Alan D. Gold said life science transaction yields below current cost of capital, this structure provides accretive transaction.